|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, Mu CY and Huang JA: Clinical
significance of programmed death-1 ligand-1 expression in patients
with non-small cell lung cancer: A 5-year-follow-up study. Tumori.
98:751–755. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Velcheti V, Schalper KA, Carvajal DE,
Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L
and Rimm DL: Programmed death ligand-1 expression in non-small cell
lung cancer. Lab Invest. 94:107–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Michot JM, Bigenwald C, Champiat S,
Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A,
Bahleda R, Hollebecque A, et al: Immune-related adverse events with
immune checkpoint blockade: A comprehensive review. Eur J Cancer.
54:139–148. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haanen JBAG, Carbonnel F, Robert C, Kerr
KM, Peters S, Larkin J and Jordan K; ESMO Guidelines Committee, :
Management of toxicities from immunotherapy: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28
(Suppl 4):iv119–iv142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kawakami H, Tanizaki J, Tanaka K, Haratani
K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T,
et al: Imaging and clinicopathological features of
nivolumab-related cholangitis in patients with non-small cell lung
cancer. Invest New Drugs. 35:529–536. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gelsomino F, Vitale G and Ardizzoni A: A
case of nivolumab-related cholangitis and literature review: How to
look for the right tools for a correct diagnosis of this rare
immune-related adverse event. Invest New Drugs. 36:144–146. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kashima J, Okuma Y, Shimizuguchi R and
Chiba K: Bile duct obstruction in a patient treated with nivolumab
as second-line chemotherapy for advanced non-small-cell lung
cancer: A case report. Cancer Immunol Immunother. 67:61–65. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuraoka N, Hara K, Terai S, Yatabe Y and
Horio Y: Peroral cholangioscopy of nivolumab-related (induced)
ulcerative cholangitis in a patient with non-small cell lung
cancer. Endoscopy. 50:E259–E261. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hellmann MD, Ciuleanu T-E, Pluzanski A,
Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H,
Burgers S, Salman P, et al: Nivolumab plus ipilimumab in lung
cancer with a high tumor mutational burden. N Engl J Med.
378:2093–2104. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abernethy AP, Arunachalam A, Burke T,
McKay C, Cao X, Sorg R and Carbone DP: Real-world first-line
treatment and overall survival in non-small cell lung cancer
without known EGFR mutations or ALK rearrangements in US community
oncology setting. PLoS One. 12:e01784202017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haratani K, Hayashi H, Chiba Y, Kudo K,
Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M and
Nakagawa K: Association of immune-related adverse events with
nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol.
4:374–378. 2017. View Article : Google Scholar
|
|
19
|
Weber JS, Kähler KC and Hauschild A:
Management of immune-related adverse events and kinetics of
response with ipilimumab. J Clin Oncol. 30:2691–2697. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim KW, Ramaiya NH, Krajewski KM,
Jagannathan JP, Tirumani SH, Srivastava A and Ibrahim N:
Ipilimumab- associated hepatitis: Imaging and clinicopathologic
findings. Invest New Drugs. 31:1071–1077. 2013. View Article : Google Scholar : PubMed/NCBI
|
